Clinical Operations in Oncology Trials West Coast

Join Nadeeka Dias, PhD, ERT’s Clinical Science Advisor for the session, “Why the Increased Use of ePRO and other eCOAs in Oncology Studies?” She will review current trends in oncology clinical studies, specifically the expansion of study endpoints to include cancer-related symptomatology, pain medication intake and overall quality of life as reported by the patient, not the clinician.  Learn why the shift to value and patient-reported endpoint data is recommended by global regulatory authorities, supported by patient preference surveys, and becoming a fundamental component of drug pricing and reimbursement policies.

Attend the session or visit us at Booth #9 to learn more.